These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008. Lingaratnam SM; Kirsa SW; Mellor JD; Jackson J; Crellin W; Fitzsimons M; Zalcberg JR Aust Health Rev; 2011 May; 35(2):204-10. PubMed ID: 21612735 [TBL] [Abstract][Full Text] [Related]
5. Aspects of the Pharmaceuticals Benefits Scheme. Baume P J Qual Clin Pract; 2001 Sep; 21(3):89-91. PubMed ID: 11892832 [No Abstract] [Full Text] [Related]
6. Pharmaceutical Benefits Scheme (PBS). Louis WJ; O'Callaghan CJ; Krum H; Mander AG; Louis ES Med J Aust; 1994 Mar; 160(5):306-7. PubMed ID: 8107635 [No Abstract] [Full Text] [Related]
7. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia. McManus P; Birkett DJ; Dudley J; Stevens A Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489 [TBL] [Abstract][Full Text] [Related]
8. Can a health care system change? Lexchin J CMAJ; 1997 Sep; 157(5):507-8. PubMed ID: 9294383 [No Abstract] [Full Text] [Related]
9. Experience with providing drugs for seniors in Canada. Gray J Am J Geriatr Cardiol; 2005; 14(6):313-6. PubMed ID: 16276129 [TBL] [Abstract][Full Text] [Related]
10. Bonanza for drug companies. Quebec's public drug plan pays for biotechnology boom. Blair L Can Fam Physician; 2002 Apr; 48():831, 833, 836-8. PubMed ID: 12046376 [No Abstract] [Full Text] [Related]
11. [The physician caught between two chairs. Comments on the difficulty in dealing with off-label use]. Harder Yv Urologe A; 2007 Oct; 46(10):1429-34. PubMed ID: 17786403 [No Abstract] [Full Text] [Related]
13. [May the family physician be informed about unapproved inpatient treatment?]. Lemke R Dtsch Med Wochenschr; 2005 Jun; 130(24):1519. PubMed ID: 15942845 [No Abstract] [Full Text] [Related]
14. Cost of pharmaceutical benefits. Mackereth MB N Z Med J; 1988 Jul; 101(849):460-1. PubMed ID: 3399187 [No Abstract] [Full Text] [Related]
15. [Insulin therapy in type 2 diabetes. Insured patients would be willing to pay for added benefits]. MMW Fortschr Med; 2008 Dec; 150(49-50):56-7. PubMed ID: 19133372 [No Abstract] [Full Text] [Related]
16. Hybrid risk adjustment for pharmaceutical benefits. García-Goñi M; Ibern P; Inoriza JM Eur J Health Econ; 2009 Jul; 10(3):299-308. PubMed ID: 19011914 [TBL] [Abstract][Full Text] [Related]
17. Expanding the breadth of Medicare: learning from Australia. Duckett S Health Econ Policy Law; 2018 Jul; 13(3-4):344-368. PubMed ID: 29362017 [TBL] [Abstract][Full Text] [Related]
18. A pharmaceutical perspective of Australia's Health Benefits Program. Elzarian EJ J Am Pharm Assoc; 1975 Dec; 15(12):695-8, 708. PubMed ID: 1206197 [No Abstract] [Full Text] [Related]
19. [Prinicipal health services accessibility risks in the European Union countries]. Moradell M; Halley des Fontaines V Sante Publique; 2000 Dec; 12(4):513-27. PubMed ID: 11349337 [TBL] [Abstract][Full Text] [Related]
20. The Australian experience with national health insurance: Part 1. Bernstein AH Hospitals; 1978 Apr; 52(7):46-8, 50, 174. PubMed ID: 631778 [No Abstract] [Full Text] [Related] [Next] [New Search]